AdjuTec Pharma AS, a privately held company developing antibiotic resistance breakers, today announces that it has entered into a research collaboration agreement with Venus Remedies Limited (India). Venus Remedies Limited will perform a pre-clinical evaluation of AdjuTec Pharma´s APC-148 platform technology. AdjuTec Pharma has developed novel
OneSource Specialty Pharma Limited today announced the appointment of three new non-executive independent directors to its Board — Dr. Claudio Albrecht, Ms. Debarati Sen and Mr. Vijay Karwal—effective February 27, 2025. The directors bring decades of leadership experience and expertise in Pharma, Business Strategy, Transformation,
Granules India Limited (BSE: 532482, NSE: GRANULES) today announced the signing of the acquisition agreement regarding Senn Chemicals AG, a Swiss-based CDMO specializing in peptides. Senn develops and manufactures, Peptides and Peptides based applications for its global customers, providing contract research, development, and manufacturing services.
Everest Group, a leading global research and consulting firm, has recognized Indegene as a front-runner in generative AI (GenAI) life sciences market adoption. In its report, 'AI-deas to Action: Operationalizing Generative AI in Life Sciences', Everest Group acknowledged Indegene’s comprehensive GenAI capabilities, including scale, breadth
Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading Indian exporter of generic drugs, has received marketing authorization from Indonesia, Southeast Asia’s largest pharmaceutical market, for its Enoxaparin in
Cotecna Life Sciences India Private Limited, formerly Geo-Chem Pharma, is proud to announce the inauguration of its new, state-of-the-art laboratory in Mumbai. This development represents a significant step in supporting the rapid growth of India’s pharmaceutical industry and demonstrates Cotecna’s dedication to fostering innovation, quality,
Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported
Q3FY25 Performance Highlights Revenues of ₹3,926 million grew 18% QoQ. EBITDA grew 85% QoQ to ₹1,432 million. EBITDA margin of 36.5% grew by 1,334 basis points QoQ. Q3 FY25 normalized PAT was ₹898 million, resulting in an EPS of ₹7.8 for the quarter. Reported PAT
Mankind Pharma, a renowned global pharmaceutical company, has set up a comprehensive healthcare camp at the Mahakumbh 2025 in Prayagraj, Uttar Pradesh, India, offering essential medical services and support to thousands of pilgrims. The initiative, which commenced on 13th January and will continue through to
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crores Syngene International Limited today announced its third quarter financial results. Reported revenue from operations was up by 11% year-on-year to Rs. 944
